About Us

Welcome to the website of Eisai (Singapore) Pte. Ltd., a pharmaceutical subsidiary of Eisai Co., Ltd. based in Tokyo, Japan.

Parent Company

Eisai Co., Ltd. was founded in Japan in 1941 as Nihon Eisai Co., Ltd. To this day, Eisai Co., Ltd. is one of the few Japanese pharmaceutical companies to undertake aggressive global expansion through substantial infrastructure investments in its foreign affiliates. These affiliates conduct research and development, manufacturing, and sales and marketing in the United States, Europe and Asia.

Eisai has more than 10,000 employees worldwide and is a publicly traded company whose stock trades on the Tokyo Stock Exchange and is listed in the United States.


Corporate Mission

Our human health care (hhc) mission, the desire to contribute to patients, is our corporate concept and the core of our business.

"We give first thought to patients and the people in the daily living domain, and increase the benefits that healthcare provides to them as well as meet their diversified healthcare needs worldwide."


Corporate Objective

A human health care company capable of making a meaningful contribution under any health care system while observing the highest legal and ethical standards in business activities.


Eisai’s hhc Philosophy

Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, treatment and care for the health and well-being of people worldwide. Our company’s hhc mission symbol is derived from the letters in Florence Nightingale’s signature. Following the example set by this famed healthcare pioneer, who devoted her life to caring for others yet never lost sight of the importance of listening to her patients, Eisai marshals its talents to explore new therapeutic approaches that help address two key goals: meeting the medical needs of patients and their families, and improving their quality of life.

Our Products


Eisai has positioned neurology and oncology as its therapeutic areas of focus, where there are many diseases for which adequate treatments have yet to be established. In order to fulfill patients’ unmet needs, Eisai sets out a goal to be a “Medico Societal Innovator” or in other words, “a company that changes society through creating medicines and providing solutions”.


Alzheimer’s Disease
Aricept Evess Orodispersible Tablet 5mg, 10mg
Donepezil Hydrochloride
Alzheimer’s Disease
Aricept Film-coated Tablet 23mg
Donepezil Hydrochloride
Fycompa Film-coated Tablet 2mg, 4mg, 8mg
Inovelon Film-coated Tablet 200mg
Peripheral Neuropathies
Methycobal Tablet 500mcg
Peripheral Neuropathies
Methycobal Injection 500mcg/ml
Multiple Sclerosis
Tysabri Concentrate for Solution for Infusion 300mg/15ml
Multiple Sclerosis
Tecfidera Gastro-resistant Hard Capsule 120mg, 240mg
Dimethyl Fumarate
Parkinson’s disease
Equfina Film-Coated Tablet 50mg
Fycompa Oral Suspension 0.5mg/ml


Pariet Tablet 10mg, 20mg
Sodium Rabeprazole
Iron-deficiency Anemia
Ferrocyte Tablet 50mg
Sodium Ferrous Citrate
Dayvigo Film-coated Tablet 5mg
Chronic Idiopathic Constipation
Goofice Film-coated Tablet 5mg


Breast Cancer / Liposarcoma
Halaven Solution for Injection 0.5mg/ml
Eribulin Mesylate
RAI-refractory Differentiated Thyroid Cancer / Renal Cell Carcinoma / Hepatocellular Carcinoma / Endometrial Carcinoma
Lenvima Hard Capsule 4mg, 10mg

Eisai (Singapore) Pte. Ltd.

152 Beach Road, #15-07/08 Gateway East, Singapore 189721

Get in touch with us

    *Please do not include any personal information "name, email address, etc." in the body of your inquiry/message.